TrialThe lancet. HIV2020

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.

Raphael J Landovitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.